2.7.5.　参考文献

Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. *J Clin Oncol.* 2008;26(13):2139-46.

Alcala AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: clinical trials and mechanisms of resistance. *Clin Cancer Res.* 2012;18(1):33-9.

Askew RL, Xing Y, Palmer JL, et al. Evaluating minimal important differences for the FACT-melanoma quality of life questionnaire. *Value in Health.* 2009;12:1144-50.

Bollag G, Hirth P,Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature.* 2010;467:596-9.

Carroll KJ. Back to basics: explaining sample size in outcome trials, are statisticians doing a thorough job?. *Pharm Stat.* 2009;8:333-45.

Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med.* 2011;364(26):2507-16.

Davies B, Morris T. Physiological parameters in laboratory animals and humans. *Pharm Res.* 1993;10 (7):1093-5.

Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. *PNAS.* 2009;106(48):20411-6.

Fedorenko IV, Paraiso KH, Smalley KS. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. *Biochem Pharmacol.* 2011;82:201-9.

Haura EB, Ricart AD, Larson TG, et al. A Phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. *Clin Cancer Res.* 2010;16(8):2450-7.

Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet.* 2012;380:358-65.

Infante JR, Papadopoulos KP, Bendell JC, et al. A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours. *Eur J Cancer.* 2013;49:2077-85.

Infante JR, Somer BG, Park JO, et al. A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. *Eur J Cancer.* 2014;50(12):2072-81.

Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. *Nature.* 2010;468(16):968-72.

Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. *J Clin Oncol.* 2008;26:527-34.

Little AS, Balmanno K, Sale MJ, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. *Sci Siqnal.* 2011;4:1-14.

LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. *Clin Cancer Res.* 2010;16(6):1924-37.

McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol.* 2014;15:323-32.

Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. *Nature.* 2010;468:973-7.

NCCN. NCCN Guidelines Version 1.2015 Panel Members Melanoma. *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Melanoma.* 2014b:.

Nissan MH, Solit DB. The “SWOT” of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both?. *Curr Oncol Rep.* 2011;13:479-87.

Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. *J Clin Oncol.* 1998;16:139-44.

Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. *Health Qual Life Outcomes.* 2007;5:1-8.

Renouf DJ, Velazquez-Martin JP, Simpson R, et al. Ocular toxicity of targeted therapies. *J Clin Oncol.* 2012;30(26):3277-86.

Solit DB, Rosen N. Resistance to BRAF inhibition in melanomas. *N Engl J Med.* 2011;364(8):772-4.

Sosman JA, Kim KB, Schuchter L,et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *N Engl J Med.* 2012;366:707-14.

Su F, Bradley WD, Wang Q, et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. *Cancer Res.* 2012a;72:969-78.

Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. *Cancer Res.* 2011;71:7137-40.

Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. *J Clin Oncol.* 2011;29:3085-96.